STScott A. Thomson

Scott A. Thomson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Scott A. Thomson has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • I. A. Ramshaw

    John Curtin School of Medical Research (JCSMR), Australian National University, Canberra, Australian Capital Territory, Australia

    2 shared publications
  • J. L. Banyer

    John Curtin School of Medical Research (JCSMR), Australian National University, Canberra, Australian Capital Territory, Australia

    2 shared publications
  • N. H. R. Hamilton

    John Curtin School of Medical Research (JCSMR), Australian National University, Canberra, Australian Capital Territory, Australia

    2 shared publications
  • S. Mahalingam

    John Curtin School of Medical Research (JCSMR), Australian National University, Canberra, Australian Capital Territory, Australia

    2 shared publications
  • A. J. Hapel

    Research School of Chemistry, Australian National University, Canberra, Australian Capital Territory; and

    1 shared publication
  • A. J. Ramsay

    Centre for Biomolecular Vaccine Technology, Discipline of Immunology and Microbiology, University of Newcastle, NSW, Australia

    1 shared publication

Latest Publications

  • Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use

    by Scott A. Thomson, Angel B. Jaramillo, Maryanne Shoobridge, Kerrie J. Dunstan, Beth Everett, Charani Ranasinghe, Stephen J. Kent, Ke Gao, Jill Medveckzy, Rosemary A. Ffrench, et al.


  • A Recombinant Vaccinia Virus Encoding the Interferon‐Inducible T‐Cell Alpha Chemoattractant is Attenuated In Vivo

    by N. H. R. Hamilton, S. Mahalingam, J. L. Banyer, I. A. Ramshaw, S. A. Thomson

    Murine interferon‐inducible T‐cell alpha chemoattractant (I‐TAC) is a potent non‐ELR CXC chemokine that predominantly attracts activated T lymphocytes, binds to the receptor CXCR3 and is induced by interferon‐γ (IFN‐γ). We analysed I‐TAC expression by reverse transcriptase‐polymerase chain reaction during three different virus‐infection models in mice, respiratory syncytial virus (RSV), influenza A and vaccinia virus western reserve (VV‐WR). In the lungs from mice infected with RSV or influenza A viruses, peak expression of I‐TAC coincided with peak viraemia. Surprisingly, there was no expression in the lungs of mice infected with vaccinia, unlike the elevated expression shown previously for other interferon‐regulated chemokines, such as Crg2 and Mig. To further investigate the importance of this difference during vaccinia infection in mice, a recombinant virus encoding I‐TAC (rVV I‐TAC) was generated. Studies in C57BL/6 and Swiss nude mice showed that I‐TAC expression caused increased mononuclear cell infiltration and significantly attenuated the VV. Infection of the footpads of naïve or already immune (with VV‐WR) mice with either rVV I‐TAC or VV‐WR demonstrated that I‐TAC expression reduced overall inflammation during infection and that this reduction was more pronounced in already immune mice. The data presented here show that I‐TAC can have an important role during virus infections and that vaccinia has evolved ways to avoid inducing I‐TAC expression.


  • Open Access

    IFN‐γ Regulates Murine Interferon‐Inducible T Cell Alpha Chemokine (I‐TAC) Expression in Dendritic Cell Lines and during Experimental Autoimmune Encephalomyelitis (EAE)

    by N. H. R. Hamilton, J. L. Banyer, A. J. Hapel, S. Mahalingam, A. J. Ramsay, I. A. Ramshaw, S. A. Thomson

    Murine interferon‐inducible T cell alpha chemokine (I‐TAC) is a potent non‐ELR Cys‐X‐Cys (CXC) chemokine that predominantly attracts activated T lymphocytes and binds to the receptor CXCR3. Using semiquantitative reverse transcription–polymerase chain reaction (RT–PCR) we analysed murine I‐TAC expression in two different progenitor dendritic cell (DC) lines, MTHC‐D2 and JAWS II which were exposed to various cytokines, and Con A‐activated splenocytes from a panel of knockout mice. Analysis of the progenitor DC lines and Con A cultures demonstrated that murine I‐TAC is primarily regulated by interferon (IFN)‐γ via interferon regulatory factor (IRF)‐1. It has been proposed that I‐TAC may have a role in autoimmune diseases such as multiple sclerosis (MS). Because I‐TAC appears to be secreted from antigen‐presenting cells (APCs) and attracts activated T cells, we examined the level of murine I‐TAC mRNA in the central nervous system (CNS) of wild‐type and IFN‐γ‐receptor knockout (IFN‐γR−/−) mice with myelin oligodendrocyte glycoprotein (MOG)35–55 peptide‐induced experimental autoimmune encephalomyelitis (EAE). Peak I‐TAC expression was detected in wild‐type mice on day 14 when the mice begin to recover, whereas very low levels of I‐TAC were detected in the CNS of IFN‐γR−/− mice which develop severe EAE and die. The expression characteristics of murine I‐TAC suggest an important mediator of immune cell communication that could augment vaccines and autoimmune therapies.